In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImmuNext Inc.

www.immunext.com

Latest From ImmuNext Inc.

Roche Dealmakers On The Immunology Technology They're Shopping For

Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.

Research and Development Strategies Deals

Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration

Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.

Deals Business Strategies

Lilly Opens Its Wallet For Early Immunology Tie-Up With ImmuNext

Lilly is prepared to splash over $600m on an early development deal with ImmuNext on an immunometabolism target which ties the companies together for three years while an antibody is being developed.

Deals Companies

Sanofi Sees Immunology Momentum Heading Toward Cures

Sanofi is looking to develop new mechanisms of action and multi-targeted approaches in immunology and inflammation, with a vision of targeting disease causes rather than symptomatic improvement.

Immune Disorders Inflammation
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ImmuNext Inc.
  • Senior Management
  • David DeLucia, CEO
    Jay Rothstein, PhD, CSO
  • Contact Info
  • ImmuNext Inc.
    1 Medical Ctr. Dr.
    Lebanon, NH 03756
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register